Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 184
interventional 137
Observational 46
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 51
Biological 27
Drug|placebo 18
Biological|placebo 9
Other 6
Procedure 5
Behavioral 4
Biological|Drug 3
Biological|Other 3
Biological|Other|placebo 2
Biological|Procedure 2
Biological|Drug|placebo 1
Device 1
Device|Other 1
Diagnostic Test 1
Drug|Genetic 1
Drug|Genetic|Other|Procedure 1
Drug|Other 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 66
NA 11
Belgium 6
France 6
China 5
United Kingdom 4
Brazil 3
Japan 3
Spain 3
Israel 2
Italy 2
Switzerland 2
United States|Puerto Rico 2
United States|United Kingdom 2
Australia 1
Australia|Austria|Belgium|Brazil|Canada|Croatia|Estonia|India|Ireland|Italy|Latvia|Mexico|New Zealand|Norway|Poland|Serbia|Spain|Switzerland|Turkey|United Kingdom|Venezuela 1
Austria|Germany 1
Belgium|Spain 1
Canada 1
Canada|Spain 1
Germany 1
Mexico 1
Singapore 1
United States|Australia|Belgium|Brazil|Canada|France|Germany|Italy|New Zealand|Poland|Romania|Spain|United Kingdom 1
United States|Australia|Brazil|France|Germany|Mexico|Spain|Sweden|United Kingdom 1
United States|Australia|Canada|Denmark|France|Germany|Italy|Sweden|Switzerland|United Kingdom 1
United States|Australia|Canada|Finland|Israel|Russian Federation|Spain 1
United States|Australia|Canada|France|Germany|Mexico|Spain 1
United States|Belgium|Canada|France|Germany|Italy|Spain|Sweden|United Kingdom 1
United States|Belgium|France|Germany|Norway|Spain|Sweden|United Kingdom 1
United States|Canada|Spain 1
United States|Finland|Mexico 1
United States|France|Germany|Italy|Japan|United Kingdom 1
United States|Mexico 1

Sites per Study

Site_count Study_Count
1 70
2 11
3 5
4 7
5 5
6 2
7 2
8 2
9 4
11 1
12 2
13 1
14 1
15 1
16 1
17 1
18 1
19 4
21 1
24 1
25 1
26 2
30 1
32 1
35 1
39 1
48 1
50 1
55 1
57 1
80 1
95 1
97 1

Phase

Phase Study_Count
Phase 1 30
N/A 27
Phase 2 27
Phase 3 21
Phase 4 20
Phase 1/Phase 2 8
Phase 2/Phase 3 3
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 42
2 51
3 8
4 4
5 1
8 1
10 1
17 1
NA 28

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 20 8.000 2.00000 16.00000 12.0000 63.00000 20.00 12.00
1st Qu. 20 38.500 18.00000 24.50000 46.5000 81.50000 130.00 37.50
Median 20 150.000 25.00000 41.00000 102.0000 100.00000 257.50 99.00
Mean 20 1215.957 40.93103 49.42857 193.1481 95.66667 330.70 122.20
3rd Qu. 20 247.000 40.00000 70.00000 141.5000 112.00000 420.25 183.75
Max. 20 23500.000 190.00000 100.00000 2100.0000 124.00000 1200.00 325.00

Trial Group Type

group_type Group_Count
Experimental 139
Placebo Comparator 37
Active Comparator 33
NA 28
Other 8
No Intervention 7

Intervention Model

intervention_model Study_Count
Parallel Assignment 62
Single Group Assignment 51
NA 21
Sequential Assignment 2
Crossover Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 65
Prevention 51
Supportive Care 9
Diagnostic 6
Other 2
Screening 2
Basic Science 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 17
NA 7
France 3
Korea, Republic of 3
Brazil 2
Canada 2
China 2
Germany 2
Israel 2
Spain 2
Australia 1
Belarus 1
Netherlands 1
Switzerland 1

Sites per Study

Site_count Study_Count
1 36
2 2
3 2
5 1
7 1
15 1
16 1
36 1
38 1

Enrollment Metrics

Measure Observational
Min 8.0000
1st Qu 75.0000
Median 120.0000
Mean 401.2195
3rd Qu 250.0000
Max 8855.0000

Observation Model

observational_model Study_Count
Cohort 20
NA 13
Case-Only 4
Case Control 3
Case-Control 2
Other 2
Family-Based 1
Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 24
NA 13
Retrospective 5
Cross-Sectional 4

Registries

Studies by Country

Country Study_Count
China 1

Sites per Study

Site_count Study_Count
4 1

Enrollment Metrics

Measure Registries
Min 1510
1st Qu 1510
Median 1510
Mean 1510
3rd Qu 1510
Max 1510

Registry Model

observational_model Study_Count
Other 1

Time Perspective

time_perspective Study_Count
Cross-Sectional 1

Follow-up

target_duration Study_Count
14 Days 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03910478 Dried Blood Spot Testing of CMV Detection in HCT Recipients https://ClinicalTrials.gov/show/NCT03910478 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2024-12-30
NCT03382405 Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults https://ClinicalTrials.gov/show/NCT03382405 Active, not recruiting ModernaTX, Inc. 2020-07-31
NCT03301415 Asymptomatic Congenital CMV Treatment https://ClinicalTrials.gov/show/NCT03301415 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2024-07-01
NCT03266640 Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) https://ClinicalTrials.gov/show/NCT03266640 Recruiting New York Medical College 2020-12-31
NCT03159364 Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections https://ClinicalTrials.gov/show/NCT03159364 Recruiting Shenzhen Geno-Immune Medical Institute 2020-07-31
NCT03067155 CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. https://ClinicalTrials.gov/show/NCT03067155 Recruiting University Hospital, Ghent 2022-12-31
NCT03004261 CMV-CTL for the Treatment of CMV Infection After HSCT https://ClinicalTrials.gov/show/NCT03004261 Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-31
NCT02985775 Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation https://ClinicalTrials.gov/show/NCT02985775 Completed Peking University People’s Hospital 2018-03-31
NCT02982902 T Cell Therapy of Opportunistic Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT02982902 Recruiting Case Comprehensive Cancer Center 2020-12-31
NCT02943057 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis https://ClinicalTrials.gov/show/NCT02943057 Recruiting Singapore National Eye Centre 2021-12-31
NCT02826798 Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults https://ClinicalTrials.gov/show/NCT02826798 Completed VBI Vaccines Inc. 2016-09-15
NCT02798692 Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV https://ClinicalTrials.gov/show/NCT02798692 Completed Hookipa Biotech 2017-05-31
NCT02784756 Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients https://ClinicalTrials.gov/show/NCT02784756 Recruiting University Health Network, Toronto 2019-12-31
NCT02683291 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients https://ClinicalTrials.gov/show/NCT02683291 Completed Associação Médico Espírita de Botucatu 2015-01-31
NCT02680743 Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit https://ClinicalTrials.gov/show/NCT02680743 Completed University of Nebraska 2018-05-31
NCT02671318 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence https://ClinicalTrials.gov/show/NCT02671318 Recruiting Hospital do Rim e Hipertensão 2019-12-31
NCT01646645 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01646645 Recruiting Memorial Sloan Kettering Cancer Center 2021-06-30
NCT02136797 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02136797 Recruiting Memorial Sloan Kettering Cancer Center 2021-06-30
NCT01251744 Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus https://ClinicalTrials.gov/show/NCT01251744 Completed GlaxoSmithKline 2013-11-06
NCT02550639 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant https://ClinicalTrials.gov/show/NCT02550639 Completed Hospital Universitari de Bellvitge 2018-09-30
NCT02506933 Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant https://ClinicalTrials.gov/show/NCT02506933 Active, not recruiting City of Hope Medical Center 2018-10-31
NCT02454699 Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers https://ClinicalTrials.gov/show/NCT02454699 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2017-04-01
NCT02396134 Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02396134 Recruiting City of Hope Medical Center 2020-05-31
NCT02351102 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy https://ClinicalTrials.gov/show/NCT02351102 Completed Rabin Medical Center 2019-07-31
NCT02328963 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A https://ClinicalTrials.gov/show/NCT02328963 Completed University Hospital, Bordeaux 2018-10-10
NCT02313857 Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) https://ClinicalTrials.gov/show/NCT02313857 Completed AlloVir 2017-05-31
NCT02210078 Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT02210078 Recruiting M.D. Anderson Cancer Center 2020-02-28
NCT02139423 Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening https://ClinicalTrials.gov/show/NCT02139423 Active, not recruiting Assistance Publique - Hôpitaux de Paris 2018-03-31
NCT02137772 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) https://ClinicalTrials.gov/show/NCT02137772 Completed Merck Sharp & Dohme Corp. 2016-08-08
NCT02134184 The Influence of Chronic CMV Infection on Influenza Vaccine Responses https://ClinicalTrials.gov/show/NCT02134184 Completed Stanford University 2012-12-31
NCT02103426 An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients https://ClinicalTrials.gov/show/NCT02103426 Completed Astellas Pharma Inc 2016-05-10
NCT02084446 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant https://ClinicalTrials.gov/show/NCT02084446 Completed Hospital Geral de Fortaleza 2014-07-31
NCT03354728 Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03354728 Recruiting City of Hope Medical Center 2021-05-11
NCT02007356 A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® https://ClinicalTrials.gov/show/NCT02007356 Recruiting University Hospital, Basel, Switzerland 2020-12-31
NCT01986010 Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) https://ClinicalTrials.gov/show/NCT01986010 Completed Merck Sharp & Dohme Corp. 2016-04-19
NCT01972035 ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation https://ClinicalTrials.gov/show/NCT01972035 Active, not recruiting University of Minnesota 2020-10-31
NCT01941056 Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus https://ClinicalTrials.gov/show/NCT01941056 Completed City of Hope Medical Center 2017-07-28
NCT01923636 Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero https://ClinicalTrials.gov/show/NCT01923636 Active, not recruiting Assistance Publique - Hôpitaux de Paris 2020-06-30
NCT01819519 Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus https://ClinicalTrials.gov/show/NCT01819519 Completed Women and Infants Hospital of Rhode Island 2015-03-31
NCT01753167 A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients https://ClinicalTrials.gov/show/NCT01753167 Completed Genentech, Inc. 2014-10-15
NCT01691820 A Study in Adolescent Females to Explore Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT01691820 Completed GlaxoSmithKline 2017-04-08
NCT01663740 A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls https://ClinicalTrials.gov/show/NCT01663740 Completed Hoffmann-La Roche 2015-09-29
NCT01649869 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss https://ClinicalTrials.gov/show/NCT01649869 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2019-12-24
NCT01611974 Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients https://ClinicalTrials.gov/show/NCT01611974 Completed Shire 2014-12-05
NCT01594437 Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody https://ClinicalTrials.gov/show/NCT01594437 Completed Theraclone Sciences, Inc. 2012-12-31
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01552369 CMV Antiviral Prevention Strategies in D+R-Liver Transplants (“CAPSIL”) https://ClinicalTrials.gov/show/NCT01552369 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2018-06-22
NCT01535885 Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV https://ClinicalTrials.gov/show/NCT01535885 Completed Medical College of Wisconsin 2019-10-31
NCT01509404 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT01509404 Completed Medical University of South Carolina 2014-12-31
NCT01376804 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT01376804 Completed Hoffmann-La Roche 2013-05-31
NCT01376778 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) https://ClinicalTrials.gov/show/NCT01376778 Active, not recruiting The George Washington University Biostatistics Center 2018-12-31
NCT01357915 Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals’ Candidate Cytomegalovirus (CMV) Vaccine https://ClinicalTrials.gov/show/NCT01357915 Completed GlaxoSmithKline 2012-09-13
NCT01354301 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate https://ClinicalTrials.gov/show/NCT01354301 Completed Hospital do Rim e Hipertensão 2014-04-30
NCT04364178 Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV https://ClinicalTrials.gov/show/NCT04364178 Recruiting University of Pittsburgh 2025-04-01
NCT04320303 CMV Infection and Immune Intervention After Transplantation https://ClinicalTrials.gov/show/NCT04320303 Recruiting Peking University People’s Hospital 2020-12-31
NCT01325636 Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus https://ClinicalTrials.gov/show/NCT01325636 Completed Assistance Publique - Hôpitaux de Paris 2014-01-31
NCT04232280 Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults https://ClinicalTrials.gov/show/NCT04232280 Active, not recruiting ModernaTX, Inc. 2021-08-31
NCT04225923 A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT04225923 Recruiting Nobelpharma 2022-01-31
NCT04153279 CMV-TCR-T Cells for CM Virus Infection After HSCT https://ClinicalTrials.gov/show/NCT04153279 Recruiting Hebei Yanda Ludaopei Hospital 2021-10-01
NCT04129398 MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) https://ClinicalTrials.gov/show/NCT04129398 Recruiting Merck Sharp & Dohme Corp. 2022-04-15
NCT04067869 Cytomegalovirus Infection in Patients With HIV-1 Infection https://ClinicalTrials.gov/show/NCT04067869 Completed University Hospital, Bordeaux 2010-12-13
NCT04030676 QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis https://ClinicalTrials.gov/show/NCT04030676 Recruiting Centre Hospitalier Universitaire de Saint Etienne 2021-01-31
NCT04017962 A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection https://ClinicalTrials.gov/show/NCT04017962 Recruiting Memorial Sloan Kettering Cancer Center 2021-07-31
NCT03973359 Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy https://ClinicalTrials.gov/show/NCT03973359 Recruiting Foundation IRCCS San Matteo Hospital 2020-07-31
NCT03950414 A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT03950414 Recruiting University of Wisconsin, Madison 2023-08-31
NCT03840174 Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) https://ClinicalTrials.gov/show/NCT03840174 Completed Merck Sharp & Dohme Corp. 2019-11-07
NCT03806764 Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient https://ClinicalTrials.gov/show/NCT03806764 Enrolling by invitation Melbourne Health 2020-03-31
NCT03798301 Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells https://ClinicalTrials.gov/show/NCT03798301 Recruiting University of Wisconsin, Madison 2023-09-01
NCT03728426 Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT03728426 Recruiting Dana-Farber Cancer Institute 2020-12-31
NCT03699254 Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients. https://ClinicalTrials.gov/show/NCT03699254 Recruiting Maimónides Biomedical Research Institute of Córdoba 2023-04-30
NCT03631316 Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir https://ClinicalTrials.gov/show/NCT03631316 Completed Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 2018-10-30
NCT03511274 Reducing Acquisition of CMV Through Antenatal Education https://ClinicalTrials.gov/show/NCT03511274 Recruiting St George’s, University of London 2020-07-31
NCT03486834 Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002) https://ClinicalTrials.gov/show/NCT03486834 Active, not recruiting Merck Sharp & Dohme Corp. 2021-05-14
NCT03475212 Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT03475212 Recruiting Children’s Hospital Los Angeles 2022-02-28
NCT01220895 Alternate Donor Study of Pre-Emptive Cellular Therapy https://ClinicalTrials.gov/show/NCT01220895 Completed Cell Medica Ltd 2013-12-31
NCT01178905 Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants https://ClinicalTrials.gov/show/NCT01178905 Completed University Hospital Tuebingen 2012-10-31
NCT01165580 A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age https://ClinicalTrials.gov/show/NCT01165580 Completed Hoffmann-La Roche 2013-09-30
NCT01077908 Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study https://ClinicalTrials.gov/show/NCT01077908 Completed Cell Medica Ltd 2014-09-30
NCT01070797 Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) https://ClinicalTrials.gov/show/NCT01070797 Completed Baylor College of Medicine 2013-05-31
NCT00947141 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) https://ClinicalTrials.gov/show/NCT00947141 Completed University College, London 2011-12-31
NCT00942305 Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients https://ClinicalTrials.gov/show/NCT00942305 Completed Chimerix 2012-01-31
NCT00881517 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection https://ClinicalTrials.gov/show/NCT00881517 Completed IRCCS Policlinico S. Matteo 2011-10-31
NCT00880789 Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus https://ClinicalTrials.gov/show/NCT00880789 Completed Baylor College of Medicine 2013-08-31
NCT03930615 Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) https://ClinicalTrials.gov/show/NCT03930615 Recruiting Merck Sharp & Dohme Corp. 2021-08-08
NCT00730769 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients https://ClinicalTrials.gov/show/NCT00730769 Completed Hospital Universitari de Bellvitge 2007-07-31
NCT00716911 Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00716911 Completed City of Hope Medical Center 2007-07-31
NCT00699868 Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients https://ClinicalTrials.gov/show/NCT00699868 Completed Assistance Publique Hopitaux De Marseille 2011-01-31
NCT00674648 Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants https://ClinicalTrials.gov/show/NCT00674648 Completed Memorial Sloan Kettering Cancer Center 2014-03-31
NCT00673868 Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants https://ClinicalTrials.gov/show/NCT00673868 Completed Milton S. Hershey Medical Center 2008-08-06
NCT00566072 The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial https://ClinicalTrials.gov/show/NCT00566072 Completed University Hospital, Ghent NA
NCT00497796 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients https://ClinicalTrials.gov/show/NCT00497796 Completed Shire 2009-05-31
NCT00466817 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections https://ClinicalTrials.gov/show/NCT00466817 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2011-12-31
NCT00461695 Influence of Persistent CMV-infection on Immune Senescence https://ClinicalTrials.gov/show/NCT00461695 Completed University of Zurich 2008-08-31
NCT00439803 A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) https://ClinicalTrials.gov/show/NCT00439803 Completed AlphaVax, Inc. 2008-07-31
NCT00435396 Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects https://ClinicalTrials.gov/show/NCT00435396 Completed GlaxoSmithKline 2008-08-27
NCT00431353 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients https://ClinicalTrials.gov/show/NCT00431353 Completed Hoffmann-La Roche 2008-08-31
NCT00411645 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients https://ClinicalTrials.gov/show/NCT00411645 Completed Shire 2008-11-30
NCT00386412 TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant https://ClinicalTrials.gov/show/NCT00386412 Completed PETHEMA Foundation 2009-09-30
NCT00377741 A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis. https://ClinicalTrials.gov/show/NCT00377741 Completed Hoffmann-La Roche 2006-06-30
NCT00374686 Study of Prophylactic Vs Preemptive Valganciclovir https://ClinicalTrials.gov/show/NCT00374686 Completed Washington University School of Medicine NA
NCT00373412 Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge https://ClinicalTrials.gov/show/NCT00373412 Completed University of California, San Francisco 2008-02-29
NCT00373165 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients https://ClinicalTrials.gov/show/NCT00373165 Completed Lower Saxony Center for Nephrology NA
NCT00372229 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation https://ClinicalTrials.gov/show/NCT00372229 Completed Hoffmann-La Roche 2015-10-31
NCT00370006 Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM https://ClinicalTrials.gov/show/NCT00370006 Completed University of California, San Francisco NA
NCT00353977 Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors https://ClinicalTrials.gov/show/NCT00353977 Completed National Institutes of Health Clinical Center (CC) 2008-03-31
NCT00294515 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients https://ClinicalTrials.gov/show/NCT00294515 Completed Hoffmann-La Roche 2008-08-31
NCT00284687 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients https://ClinicalTrials.gov/show/NCT00284687 Completed Hadassah Medical Organization 2010-03-31
NCT00264290 Valganciclovir to Reduce T Cell Activation in HIV Infection https://ClinicalTrials.gov/show/NCT00264290 Completed University of California, San Francisco 2008-10-31
NCT00227370 Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation https://ClinicalTrials.gov/show/NCT00227370 Completed Duke University 2008-04-30
NCT00223925 Maribavir for Prevention of CMV After Stem Cell Transplants https://ClinicalTrials.gov/show/NCT00223925 Completed Shire 2006-04-30
NCT00133497 gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females https://ClinicalTrials.gov/show/NCT00133497 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2013-06-30
NCT00125502 Recombinant CMV gB Vaccine in Postpartum Women https://ClinicalTrials.gov/show/NCT00125502 Completed University of Alabama at Birmingham 2007-06-30
NCT00090766 A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients https://ClinicalTrials.gov/show/NCT00090766 Completed Hoffmann-La Roche 2005-05-31
NCT00078533 Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078533 Completed Baylor College of Medicine 2010-07-31
NCT00016068 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00016068 Completed Fred Hutchinson Cancer Research Center NA
NCT00001890 Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections https://ClinicalTrials.gov/show/NCT00001890 Completed National Institutes of Health Clinical Center (CC) NA
NCT00031434 Valganciclovir in Congenital CMV Infants https://ClinicalTrials.gov/show/NCT00031434 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2007-07-31
NCT00006145 Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV https://ClinicalTrials.gov/show/NCT00006145 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00002373 The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients https://ClinicalTrials.gov/show/NCT00002373 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002352 A Study of Lobucavir in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002352 Completed Bristol-Myers Squibb NA
NCT00002268 A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria https://ClinicalTrials.gov/show/NCT00002268 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002251 A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir https://ClinicalTrials.gov/show/NCT00002251 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002146 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study https://ClinicalTrials.gov/show/NCT00002146 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002096 A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine https://ClinicalTrials.gov/show/NCT00002096 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002095 A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus https://ClinicalTrials.gov/show/NCT00002095 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002025 Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient https://ClinicalTrials.gov/show/NCT00002025 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002024 Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections https://ClinicalTrials.gov/show/NCT00002024 Completed NIH AIDS Clinical Trials Information Service NA
NCT00001100 A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. https://ClinicalTrials.gov/show/NCT00001100 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00001082 The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients https://ClinicalTrials.gov/show/NCT00001082 Completed National Institute of Allergy and Infectious Diseases (NIAID) 1999-01-31
NCT00001038 A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients https://ClinicalTrials.gov/show/NCT00001038 Completed National Institute of Allergy and Infectious Diseases (NIAID) 1996-05-31
NCT00000995 A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection https://ClinicalTrials.gov/show/NCT00000995 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000981 The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS https://ClinicalTrials.gov/show/NCT00000981 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000805 A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease https://ClinicalTrials.gov/show/NCT00000805 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00004642 Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease https://ClinicalTrials.gov/show/NCT00004642 Completed Office of Rare Diseases (ORD) NA
NCT00000593 Viral Activation Transfusion Study (VATS) https://ClinicalTrials.gov/show/NCT00000593 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00000584 Transfusion-Transmitted Cytomegalovirus Prevention in Neonates https://ClinicalTrials.gov/show/NCT00000584 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00004278 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT00004278 Completed Office of Rare Diseases (ORD) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02782988 Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV https://ClinicalTrials.gov/show/NCT02782988 Recruiting Institut Pasteur 2020-05-31
NCT02715752 A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin https://ClinicalTrials.gov/show/NCT02715752 Completed The Center for the Biology of Chronic Disease 2016-03-31
NCT02683096 Screening for Congenital Cytomegalovirus Infection in Newborns https://ClinicalTrials.gov/show/NCT02683096 Completed Southern Illinois University 2018-02-28
NCT02645396 A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China https://ClinicalTrials.gov/show/NCT02645396 Completed Xiamen University 2018-06-30
NCT02600065 Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy https://ClinicalTrials.gov/show/NCT02600065 Recruiting University of Erlangen-Nürnberg Medical School 2020-12-31
NCT02439372 Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis https://ClinicalTrials.gov/show/NCT02439372 Completed Asan Medical Center 2016-06-30
NCT02156479 Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients https://ClinicalTrials.gov/show/NCT02156479 Completed Lophius Biosciences GmbH 2018-04-30
NCT02081716 Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT) https://ClinicalTrials.gov/show/NCT02081716 Completed Asan Medical Center 2015-11-30
NCT02076971 Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive https://ClinicalTrials.gov/show/NCT02076971 Completed Fundacio Catalana de Pneumologia 2016-03-31
NCT02067169 A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era. https://ClinicalTrials.gov/show/NCT02067169 Completed University Hospital, Limoges 2016-05-31
NCT02062294 An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients https://ClinicalTrials.gov/show/NCT02062294 Completed Hoffmann-La Roche 2011-09-30
NCT01602614 Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection https://ClinicalTrials.gov/show/NCT01602614 Completed University of Alabama at Birmingham 2019-03-31
NCT04392297 Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals https://ClinicalTrials.gov/show/NCT04392297 Enrolling by invitation The Republican Research and Practical Center for Epidemiology and Microbiology 2021-06-30
NCT03916497 Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients https://ClinicalTrials.gov/show/NCT03916497 Recruiting University Hospital, Grenoble 2019-10-31
NCT03858907 Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV https://ClinicalTrials.gov/show/NCT03858907 Recruiting University of Sao Paulo General Hospital 2020-08-05
NCT03698435 (Val)Ganciclovir TDM in Transplant Recipients https://ClinicalTrials.gov/show/NCT03698435 Recruiting University Medical Center Groningen 2019-11-30
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01081379 The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection https://ClinicalTrials.gov/show/NCT01081379 Recruiting Shaare Zedek Medical Center 2021-08-31
NCT01034709 Evaluation of the Artus® CMV PCR Test https://ClinicalTrials.gov/show/NCT01034709 Completed QIAGEN Gaithersburg, Inc 2013-09-30
NCT00907686 TT-CMV Observational Birth Cohort Study https://ClinicalTrials.gov/show/NCT00907686 Completed Emory University 2014-04-30
NCT00872703 Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection? https://ClinicalTrials.gov/show/NCT00872703 Completed Wolfson Medical Center 2008-12-31
NCT02025335 Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT02025335 Completed Asan Medical Center 2015-09-30
NCT02642822 The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University https://ClinicalTrials.gov/show/NCT02642822 Completed Xiamen University 2016-04-30
NCT01573039 Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT01573039 Completed University of Sao Paulo General Hospital 2012-11-30
NCT00815165 Cytomegalovirus Cell-Mediated Immunity https://ClinicalTrials.gov/show/NCT00815165 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2011-08-31
NCT00436384 Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients https://ClinicalTrials.gov/show/NCT00436384 Completed University Health Network, Toronto 2008-03-31
NCT00273143 A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. https://ClinicalTrials.gov/show/NCT00273143 Completed Mayo Clinic 2007-04-30
NCT00194155 Cytomegalovirus (CMV) Infection in Pregnancy https://ClinicalTrials.gov/show/NCT00194155 Completed University of Pennsylvania 2008-02-29
NCT00194142 Cytomegalovirus (CMV) Infection in Amniotic Fluid https://ClinicalTrials.gov/show/NCT00194142 Completed University of Pennsylvania 2008-05-31
NCT00170170 Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation https://ClinicalTrials.gov/show/NCT00170170 Completed Mayo Clinic 2007-06-30
NCT00168259 Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals https://ClinicalTrials.gov/show/NCT00168259 Completed The Alfred NA
NCT02324244 CMV Intensive Care Units https://ClinicalTrials.gov/show/NCT02324244 Completed Hospital General Universitario Gregorio Marañon 2013-05-31
NCT00001531 Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction https://ClinicalTrials.gov/show/NCT00001531 Completed National Institutes of Health Clinical Center (CC) NA
NCT00034437 Immune Response to Cytomegalovirus https://ClinicalTrials.gov/show/NCT00034437 Completed National Institutes of Health Clinical Center (CC) NA
NCT00031421 Neonatal CMV-Ganciclovir Follow-up Study https://ClinicalTrials.gov/show/NCT00031421 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00029406 Transfusion Infections Pediatric Prospective Study (TRIPPS) https://ClinicalTrials.gov/show/NCT00029406 Completed Children’s National Research Institute 2013-04-30
NCT00005572 A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection https://ClinicalTrials.gov/show/NCT00005572 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00817908 Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients https://ClinicalTrials.gov/show/NCT00817908 Completed University of Alberta 2012-03-31
NCT00001089 A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients https://ClinicalTrials.gov/show/NCT00001089 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00023036 Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts https://ClinicalTrials.gov/show/NCT00023036 Completed National Institutes of Health Clinical Center (CC) NA
NCT00006314 Cytomegalovirus Spread and Reactivation in Blood Cells https://ClinicalTrials.gov/show/NCT00006314 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005547 Infection and Cardiovascular Disease https://ClinicalTrials.gov/show/NCT00005547 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005496 Inflammation, Infection, and Future Cardiovascular Risk https://ClinicalTrials.gov/show/NCT00005496 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005309 Prospective Study of HIV Infection in Hemophiliacs https://ClinicalTrials.gov/show/NCT00005309 Completed Bloodworks 1995-03-31
NCT00005274 Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2) https://ClinicalTrials.gov/show/NCT00005274 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00001976 Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection https://ClinicalTrials.gov/show/NCT00001976 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02710864 A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China https://ClinicalTrials.gov/show/NCT02710864 Completed Xiamen University 2016-03-31